VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Sep 24, 2007 -- Pacgen Biopharmaceuticals Corporation ("Pacgen") (CDNX:PGA.V - News) announced today its plans for a Phase IIb dose-ranging clinical trial for an optimized formulation of PAC-113, a novel treatment for oral Candidiasis infection, and released the final results from the previously completed Phase I/II trial.
